{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:11:52Z","timestamp":1792793512999,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T00:00:00Z","timestamp":1753574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T00:00:00Z","timestamp":1753574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1245\/s10434-025-17859-9","type":"journal-article","created":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T17:27:23Z","timestamp":1753637243000},"page":"8411-8420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Surgical Choice among Women with a First Breast Cancer and Pathogenic Variants in Breast Cancer Genes"],"prefix":"10.1245","volume":"32","author":[{"given":"Lauren","family":"Kerivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Nye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Balanoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Jeffers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndsey","family":"Kilgore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-9459","authenticated-orcid":false,"given":"Kelsey","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,27]]},"reference":[{"issue":"1","key":"17859_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345. https:\/\/doi.org\/10.3322\/caac.21871.","journal-title":"CA Cancer J Clin"},{"issue":"13","key":"17859_CR2","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/jco.2015.65.0747","volume":"34","author":"N Tung","year":"2016","unstructured":"Tung N, Lin NU, Kidd J, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol. 2016;34(13):1460\u20138. https:\/\/doi.org\/10.1200\/jco.2015.65.0747.","journal-title":"J Clin Oncol."},{"issue":"11","key":"17859_CR3","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z","volume":"77","author":"EB Claus","year":"1996","unstructured":"Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996;77(11):2318\u201324.","journal-title":"Cancer"},{"issue":"5","key":"17859_CR4","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa2005936","volume":"384","author":"C Hu","year":"2021","unstructured":"Hu C, Hart SN, Gnanaolivu R, et al. A population-based study of genes previously implicated in breast cancer. N Engl J Med. 2021;384(5):440\u201351. https:\/\/doi.org\/10.1056\/NEJMoa2005936.","journal-title":"N Engl J Med."},{"issue":"6","key":"17859_CR5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.18.01631","volume":"37","author":"PD Beitsch","year":"2018","unstructured":"Beitsch PD, Whitworth PW, Hughes K, et al. Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clinic Oncol. 2018;37(6):453\u201360. https:\/\/doi.org\/10.1200\/JCO.18.01631.","journal-title":"J Clinic Oncol"},{"issue":"23","key":"17859_CR6","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 Mutation Carriers. Jama. 2017;317(23):2402\u201316. https:\/\/doi.org\/10.1001\/jama.2017.7112.","journal-title":"Jama"},{"issue":"5","key":"17859_CR7","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"A Antoniou","year":"2003","unstructured":"Antoniou A, Pharoah PDP, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Human Genet. 2003;72(5):1117\u201330. https:\/\/doi.org\/10.1086\/375033.","journal-title":"Am J Human Genet"},{"issue":"5","key":"17859_CR8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1913948","volume":"384","author":"L Dorling","year":"2021","unstructured":"Dorling L, Carvalho S, Allen J, et al. Breast cancer risk genes\u2014association analysis in more than 113,000 Women. N Engl J Med. 2021;384(5):428\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1913948.","journal-title":"N Engl J Med."},{"issue":"10","key":"17859_CR9","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1245\/s10434-019-07549-8","volume":"26","author":"ER Manahan","year":"2019","unstructured":"Manahan ER, Kuerer HM, Sebastian M, et al. Consensus guidelines on genetic` testing for hereditary breast cancer from the American society of breast surgeons. Anna Surg Oncol. 2019;26(10):3025\u201331. https:\/\/doi.org\/10.1245\/s10434-019-07549-8.","journal-title":"Anna Surg Oncol"},{"issue":"5","key":"17859_CR10","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1200\/JCO.23.02225","volume":"42","author":"I Bedrosian","year":"2024","unstructured":"Bedrosian I, Somerfield MR, Achatz MI, et al. Germline testing in patients with breast cancer: ASCO\u2013society of surgical oncology guideline. J Clinic Oncol. 2024;42(5):584\u2013604. https:\/\/doi.org\/10.1200\/JCO.23.02225.","journal-title":"J Clinic Oncol"},{"key":"17859_CR11","unstructured":"National Comprehensive Cancer Network. Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 3.2025, NCCN Clinical Practice Guidelines in Oncology. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bopp.pdf. Accessed 1 Apr 2025."},{"issue":"10","key":"17859_CR12","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1245\/s10434-016-5443-5","volume":"23","author":"JC Boughey","year":"2016","unstructured":"Boughey JC, Attai DJ, Chen SL, et al. Contralateral prophylactic mastectomy (CPM) consensus statement from the American society of breast surgeons: data on CPM outcomes and risks. Ann Surg Oncol. 2016;23(10):3100\u20135. https:\/\/doi.org\/10.1245\/s10434-016-5443-5.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"17859_CR13","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1001\/jamaoncol.2024.2212","volume":"10","author":"V Giannakeas","year":"2024","unstructured":"Giannakeas V, Lim DW, Narod SA. Bilateral mastectomy and breast cancer mortality. JAMA Oncol. 2024;10(9):1228\u201336. https:\/\/doi.org\/10.1001\/jamaoncol.2024.2212.","journal-title":"JAMA Oncol"},{"issue":"4","key":"17859_CR14","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/s0360-3016(03)00203-7","volume":"56","author":"X Gao","year":"2003","unstructured":"Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys. 2003;56(4):1038\u201345. https:\/\/doi.org\/10.1016\/s0360-3016(03)00203-7.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"17859_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13058-021-01400-3","volume":"23","author":"C Ramin","year":"2021","unstructured":"Ramin C, Withrow DR, Davis Lynn BC, Gierach GL, Berrington de Gonz\u00e1lez A. Risk of contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992\u20132016. Breast Cancer Res. 2021;23(1):24. https:\/\/doi.org\/10.1186\/s13058-021-01400-3.","journal-title":"Breast Cancer Res"},{"issue":"9","key":"17859_CR16","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1200\/JCO.22.01239","volume":"41","author":"S Yadav","year":"2023","unstructured":"Yadav S, Boddicker NJ, Na J, et al. Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. J Clinic Oncol. 2023;41(9):1703\u201313. https:\/\/doi.org\/10.1200\/JCO.22.01239.","journal-title":"J Clinic Oncol"},{"issue":"5","key":"17859_CR17","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/bjc.2014.306","volume":"111","author":"M Kriege","year":"2014","unstructured":"Kriege M, Hollestelle A, Jager A, et al. Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy. Br J Cancer. 2014;111(5):1004\u201313. https:\/\/doi.org\/10.1038\/bjc.2014.306.","journal-title":"Br J Cancer"},{"issue":"3","key":"17859_CR18","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.ajhg.2023.02.003","volume":"110","author":"A Morra","year":"2023","unstructured":"Morra A, Mavaddat N, Muranen TA, et al. The impact of coding germline variants on contralateral breast cancer risk and survival. Am J Hum Genet. 2023;110(3):475\u201386. https:\/\/doi.org\/10.1016\/j.ajhg.2023.02.003.","journal-title":"Am J Hum Genet."},{"issue":"5","key":"17859_CR19","doi-asserted-by":"publisher","first-page":"e4344","DOI":"10.1097\/gox.0000000000004344","volume":"10","author":"MS Shaheen","year":"2022","unstructured":"Shaheen MS, Momeni A. Nationwide trends in contralateral prophylactic mastectomies: an analysis of 55,060 unilateral breast cancer patients. Plast Reconstr Surg Glob Open. 2022;10(5):e4344. https:\/\/doi.org\/10.1097\/gox.0000000000004344.","journal-title":"Plast Reconstr Surg Glob Open"},{"issue":"3","key":"17859_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/SLA.0000000000001698","volume":"265","author":"SM Wong","year":"2017","unstructured":"Wong SM, Freedman RA, Sagara Y, Aydogan F, Barry WT, Golshan M. Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer. Ann Surg. 2017;265(3):47.","journal-title":"Ann Surg"},{"issue":"33","key":"17859_CR21","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1200\/jco.2007.12.3141","volume":"25","author":"TM Tuttle","year":"2007","unstructured":"Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol. 2007;25(33):5203\u20139. https:\/\/doi.org\/10.1200\/jco.2007.12.3141.","journal-title":"J Clin Oncol"},{"issue":"9","key":"17859_CR22","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1001\/jama.2014.10707","volume":"312","author":"AW Kurian","year":"2014","unstructured":"Kurian AW, Lichtensztajn DY, Keegan THM, Nelson DO, Clarke CA, Gomez SL. Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998\u20132011. Jama. 2014;312(9):902\u201314. https:\/\/doi.org\/10.1001\/jama.2014.10707.","journal-title":"Jama"},{"key":"17859_CR23","doi-asserted-by":"publisher","first-page":"116005","DOI":"10.1016\/j.amjsurg.2024.116005","volume":"239","author":"EJ Olunuga","year":"2025","unstructured":"Olunuga EJ, Thomas SM, Ntowe KW, et al. The association of genetic testing timing and mutation type on breast cancer management in patients with breast cancer-related mutations. Am J Surg. 2025;239:116005. https:\/\/doi.org\/10.1016\/j.amjsurg.2024.116005.","journal-title":"Am J Surg."},{"issue":"11","key":"17859_CR24","doi-asserted-by":"publisher","first-page":"7290","DOI":"10.1245\/s10434-024-15793-w","volume":"31","author":"KW Ntowe","year":"2024","unstructured":"Ntowe KW, Thomas SM, Dalton JC, et al. Demographics and clinical decision making in patients with germline moderate penetrance Non-BRCA mutations in breast cancer related genes. Ann Surg Oncol. 2024;31(11):7290\u2013300. https:\/\/doi.org\/10.1245\/s10434-024-15793-w.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"17859_CR25","doi-asserted-by":"publisher","first-page":"6990","DOI":"10.1245\/s10434-023-14141-8","volume":"30","author":"JQ Zhang","year":"2023","unstructured":"Zhang JQ, Dos Anjos CH, Sevilimedu V, et al. Association of moderate-risk breast cancer genes with contralateral prophylactic mastectomy and bilateral disease. Ann Surg Oncol. 2023;30(12):6990\u20139. https:\/\/doi.org\/10.1245\/s10434-023-14141-8.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"17859_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1001\/jamaoncol.2022.5162","volume":"9","author":"S Reid","year":"2023","unstructured":"Reid S, Roberson ML, Koehler K, et al. Receipt of bilateral mastectomy among women with hereditary breast cancer. Jama Oncol. 2023;9(1):143\u20135. https:\/\/doi.org\/10.1001\/jamaoncol.2022.5162.","journal-title":"Jama Oncol"},{"key":"17859_CR27","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ygyno.2022.12.012","volume":"170","author":"SS Lee","year":"2023","unstructured":"Lee SS, Karpel HC, Oh C, Smith J, Pothuri B. Beyond BRCA: patterns of risk-reducing surgery for non-BRCA, homologous recombination repair pathway gene variant carriers. Gynecol Oncol. 2023;170:234\u201340. https:\/\/doi.org\/10.1016\/j.ygyno.2022.12.012.","journal-title":"Gynecol Oncol"},{"key":"17859_CR28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cancergen.2022.07.003","volume":"266\u2013267","author":"AB Vargason","year":"2022","unstructured":"Vargason AB, Turner CE, Shriver CD, Ellsworth RE. Influence of germline test results on surgical decision making in women with invasive breast cancer. Cancer Genet. 2022;266\u2013267:81\u20135. https:\/\/doi.org\/10.1016\/j.cancergen.2022.07.003.","journal-title":"Cancer Genet"},{"key":"17859_CR29","doi-asserted-by":"publisher","first-page":"918757","DOI":"10.3389\/fonc.2022.918757","volume":"12","author":"L Turza","year":"2022","unstructured":"Turza L, Lovejoy LA, Turner CE, Shriver CD, Ellsworth RE. Eligibility, uptake and response to germline genetic testing in women with DCIS. Orig Res Front Oncol. 2022;12:918757. https:\/\/doi.org\/10.3389\/fonc.2022.918757.","journal-title":"Orig Res Front Oncol"},{"issue":"2","key":"17859_CR30","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10549-022-06619-y","volume":"194","author":"SA Sanoba","year":"2022","unstructured":"Sanoba SA, Thull DL, McAuliffe PF, et al. Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy. Breast Cancer Res Treat. 2022;194(2):393\u2013401. https:\/\/doi.org\/10.1007\/s10549-022-06619-y.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"17859_CR31","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1200\/op.21.00322","volume":"18","author":"V Ro","year":"2022","unstructured":"Ro V, McGuinness JE, Guo B, et al. Association between genetic testing for hereditary breast cancer and contralateral prophylactic mastectomy among multiethnic women diagnosed with early-stage breast cancer. JCO Oncol Pract. 2022;18(4):e472\u201383. https:\/\/doi.org\/10.1200\/op.21.00322.","journal-title":"JCO Oncol Pract"},{"issue":"10","key":"17859_CR32","doi-asserted-by":"publisher","first-page":"e2031","DOI":"10.1002\/mgg3.2031","volume":"10","author":"JG Comeaux","year":"2022","unstructured":"Comeaux JG, Culver JO, Lee JE, et al. Risk-reducing mastectomy decisions among women with mutations in high- and moderate- penetrance breast cancer susceptibility genes. Mol Genet Genomic Med. 2022;10(10):e2031. https:\/\/doi.org\/10.1002\/mgg3.2031.","journal-title":"Mol Genet Genomic Med"},{"issue":"6","key":"17859_CR33","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1245\/s10434-020-09158-2","volume":"28","author":"C Bergstrom","year":"2021","unstructured":"Bergstrom C, Pence C, Berg J, et al. Clinicopathological features and outcomes in individuals with breast cancer and ATM, CHEK2, or PALB2 mutations. Ann Surg Oncol. 2021;28(6):3383\u201393. https:\/\/doi.org\/10.1245\/s10434-020-09158-2.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"17859_CR34","doi-asserted-by":"publisher","first-page":"4613","DOI":"10.1245\/s10434-020-08889-6","volume":"27","author":"BL Murphy","year":"2020","unstructured":"Murphy BL, Yi M, Arun BK, Gutierrez Barrera AM, Bedrosian I. Contralateral risk-reducing mastectomy in breast cancer patients who undergo multigene panel testing. Ann Surg Oncol. 2020;27(12):4613\u201321. https:\/\/doi.org\/10.1245\/s10434-020-08889-6.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"17859_CR35","doi-asserted-by":"publisher","first-page":"e196400","DOI":"10.1001\/jamaoncol.2019.6400","volume":"6","author":"AW Kurian","year":"2020","unstructured":"Kurian AW, Ward KC, Abrahamse P, et al. Association of germline genetic testing results with locoregional and systemic therapy in patients with breast cancer. Jama Oncol. 2020;6(4):e196400\u2013e196400. https:\/\/doi.org\/10.1001\/jamaoncol.2019.6400.","journal-title":"Jama Oncol"},{"issue":"11","key":"17859_CR36","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1245\/s10434-014-3747-x","volume":"21","author":"N Elsayegh","year":"2014","unstructured":"Elsayegh N, Kuerer HM, Lin H, et al. Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing. Ann Surg Oncol. 2014;21(11):3466\u201372. https:\/\/doi.org\/10.1245\/s10434-014-3747-x.","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"17859_CR37","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1200\/jco.2004.04.086","volume":"22","author":"MD Schwartz","year":"2004","unstructured":"Schwartz MD, Lerman C, Brogan B, et al. Impact of BRCA1\/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol. 2004;22(10):1823\u20139. https:\/\/doi.org\/10.1200\/jco.2004.04.086.","journal-title":"J Clin Oncol"},{"issue":"1","key":"17859_CR38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10549-019-05515-2","volume":"180","author":"M Tynan","year":"2020","unstructured":"Tynan M, Peshkin BN, Isaacs C, et al. Predictors of contralateral prophylactic mastectomy in genetically high risk newly diagnosed breast cancer patients. Breast Cancer Res Treat. 2020;180(1):177\u201385. https:\/\/doi.org\/10.1007\/s10549-019-05515-2.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"17859_CR39","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/sj.bjc.6602703","volume":"93","author":"TC van Sprundel","year":"2005","unstructured":"van Sprundel TC, Schmidt MK, Rookus MA, et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer. 2005;93(3):287\u201392. https:\/\/doi.org\/10.1038\/sj.bjc.6602703.","journal-title":"Br J Cancer"},{"key":"17859_CR40","doi-asserted-by":"publisher","first-page":"g226","DOI":"10.1136\/bmj.g226","volume":"348","author":"K Metcalfe","year":"2014","unstructured":"Metcalfe K, Gershman S, Ghadirian P, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. 2014;348:g226. https:\/\/doi.org\/10.1136\/bmj.g226.","journal-title":"BMJ."},{"issue":"2","key":"17859_CR41","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10549-020-05699-y","volume":"182","author":"D Cragun","year":"2020","unstructured":"Cragun D, Weidner A, Tezak A, Clouse K, Pal T. Cancer risk management among female BRCA1\/2, PALB2, CHEK2, and ATM carriers. Breast Cancer Res Treat. 2020;182(2):421\u20138. https:\/\/doi.org\/10.1007\/s10549-020-05699-y.","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"17859_CR42","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1200\/JCO.19.01907","volume":"38","author":"X Yang","year":"2019","unstructured":"Yang X, Leslie G, Doroszuk A, et al. Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. J Clinic Oncol. 2019;38(7):674\u201385. https:\/\/doi.org\/10.1200\/JCO.19.01907.","journal-title":"J Clinic Oncol"},{"issue":"5","key":"17859_CR43","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1136\/jmedgenet-2019-106739","volume":"58","author":"H Song","year":"2021","unstructured":"Song H, Dicks EM, Tyrer J, et al. Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer. J Med Genet. 2021;58(5):305. https:\/\/doi.org\/10.1136\/jmedgenet-2019-106739.","journal-title":"J Med Genet"},{"key":"17859_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010140","author":"V Teoh","year":"2020","unstructured":"Teoh V, Tasoulis M-K, Gui G. Contralateral prophylactic mastectomy in women with unilateral breast cancer who are genetic carriers have a strong family history or are just young at presentation. Cancers. 2020. https:\/\/doi.org\/10.3390\/cancers12010140.","journal-title":"Cancers"},{"key":"17859_CR45","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.breast.2021.08.015","volume":"60","author":"DG Evans","year":"2021","unstructured":"Evans DG, Gandhi A, Wisely J, et al. Uptake of bilateral-risk-reducing-mastectomy: prospective analysis of 7195 women at high-risk of breast cancer. Breast. 2021;60:45\u201352. https:\/\/doi.org\/10.1016\/j.breast.2021.08.015.","journal-title":"Breast"},{"issue":"10","key":"17859_CR46","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1245\/s10434-010-1136-7","volume":"17","author":"JC Boughey","year":"2010","unstructured":"Boughey JC, Hoskin TL, Degnim AC, et al. Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol. 2010;17(10):2702\u20139. https:\/\/doi.org\/10.1245\/s10434-010-1136-7.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"17859_CR47","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/ijc.29032","volume":"136","author":"BA Heemskerk-Gerritsen","year":"2015","unstructured":"Heemskerk-Gerritsen BA, Rookus MA, Aalfs CM, et al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1\/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer. 2015;136(3):668\u201377. https:\/\/doi.org\/10.1002\/ijc.29032.","journal-title":"Int J Cancer"},{"issue":"7","key":"17859_CR48","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1001\/jamasurg.2017.0115","volume":"152","author":"R Nash","year":"2017","unstructured":"Nash R, Goodman M, Lin CC, et al. State variation in the receipt of a contralateral prophylactic mastectomy among women who received a diagnosis of invasive unilateral early-stage breast cancer in the United States, 2004\u20132012. Jama Surg. 2017;152(7):648\u201357. https:\/\/doi.org\/10.1001\/jamasurg.2017.0115.","journal-title":"Jama Surg"},{"key":"17859_CR49","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.breast.2018.05.001","volume":"40","author":"Q You","year":"2018","unstructured":"You Q, Chen K, Li Y, et al. Factors associated with the increasing trend of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ: analysis of surveillance, epidemiology, and end results data. Breast. 2018;40:147\u201355. https:\/\/doi.org\/10.1016\/j.breast.2018.05.001.","journal-title":"Breast"},{"issue":"4","key":"17859_CR50","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1245\/s10434-024-14893-x","volume":"31","author":"P Singh","year":"2024","unstructured":"Singh P, Agnese D, Amin M, et al. Society of surgical oncology breast disease site working group statement on contralateral mastectomy: indications, outcomes, and risks. Ann Surg Oncol. 2024;31(4):2212\u201323. https:\/\/doi.org\/10.1245\/s10434-024-14893-x.","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"17859_CR51","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/jamasurg.2020.3325","volume":"155","author":"SM Rosenberg","year":"2020","unstructured":"Rosenberg SM, Dominici LS, Gelber S, et al. Association of breast cancer surgery with quality of life and psychosocial well-being in young breast cancer survivors. Jama Surg. 2020;155(11):1035\u201342. https:\/\/doi.org\/10.1001\/jamasurg.2020.3325.","journal-title":"Jama Surg"},{"issue":"17","key":"17859_CR52","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1016\/j.ejca.2012.04.023","volume":"48","author":"D Unukovych","year":"2012","unstructured":"Unukovych D, Sandelin K, Liljegren A, et al. Contralateral prophylactic mastectomy in breast cancer patients with a family history: a prospective 2\u00a0years follow-up study of health related quality of life, sexuality and body image. Eur J Cancer. 2012;48(17):3150\u20136. https:\/\/doi.org\/10.1016\/j.ejca.2012.04.023.","journal-title":"Eur J Cancer"},{"issue":"6","key":"17859_CR53","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1245\/s10434-016-5753-7","volume":"24","author":"C Anderson","year":"2017","unstructured":"Anderson C, Islam JY, Elizabeth Hodgson M, et al. Long-term satisfaction and body image after contralateral prophylactic mastectomy. Ann Surg Oncol. 2017;24(6):1499\u2013506. https:\/\/doi.org\/10.1245\/s10434-016-5753-7.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"17859_CR54","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1245\/s10434-022-11756-1","volume":"29","author":"S Shubeck","year":"2022","unstructured":"Shubeck S, Sevilimedu V, Berger E, Robson M, Heerdt AS, Pilewskie ML. Comparison of outcomes between BRCA pathogenic variant carriers undergoing breast-conserving surgery versus mastectomy. Ann Surg Oncol. 2022;29(8):4706\u201313. https:\/\/doi.org\/10.1245\/s10434-022-11756-1.","journal-title":"Ann Surg Oncol."},{"issue":"18","key":"17859_CR55","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1200\/JCO.20.00299","volume":"38","author":"NM Tung","year":"2020","unstructured":"Tung NM, Boughey JC, Pierce LJ, et al. Management of hereditary breast cancer: american society of clinical oncology, American society for radiation oncology, and society of surgical oncology guideline. J Clinic Oncol. 2020;38(18):2080\u2013106. https:\/\/doi.org\/10.1200\/JCO.20.00299.","journal-title":"J Clinic Oncol"},{"issue":"1","key":"17859_CR56","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10549-018-5057-7","volume":"174","author":"DA Henry","year":"2019","unstructured":"Henry DA, Lee MC, Almanza D, et al. Trends in use of bilateral prophylactic mastectomy vs high-risk surveillance in unaffected carriers of inherited breast cancer syndromes in the Inherited Cancer Registry (ICARE). Breast Cancer Res Treat. 2019;174(1):39\u201345. https:\/\/doi.org\/10.1007\/s10549-018-5057-7.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"17859_CR57","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/tbj.13293","volume":"25","author":"SP Lazow","year":"2019","unstructured":"Lazow SP, Riba L, Alapati A, James TA. Comparison of breast-conserving therapy vs mastectomy in women under age 40: National trends and potential survival implications. Breast J. 2019;25(4):578\u201384. https:\/\/doi.org\/10.1111\/tbj.13293.","journal-title":"Breast J."},{"issue":"Suppl 1","key":"17859_CR58","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10552-023-01689-9","volume":"34","author":"MM Wahlen","year":"2023","unstructured":"Wahlen MM, Lizarraga IM, Kahl AR, et al. Effect of rurality and travel distance on contralateral prophylactic mastectomy for unilateral breast cancer. Cancer Causes Control. 2023;34(Suppl 1):171\u201386. https:\/\/doi.org\/10.1007\/s10552-023-01689-9.","journal-title":"Cancer Causes Control"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17859-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17859-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17859-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T16:06:32Z","timestamp":1759507592000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17859-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,27]]},"references-count":58,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["17859"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17859-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,27]]},"assertion":[{"value":"2 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Lauren Nye is a member of the Advisory Board of Myriad Genetic Laboratories. Lauren Kerivan, Jamie Wagner, Christa Balanoff, Elizabeth Jeffers, Lyndsey Kilgore, and Kelsey Larson have no disclosures to declare that may be relevant to the contents of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}